We are live on
!
Find out more
DA
DCF Advisers Portfolio holdings
AUM
$375M
1-Year Est. Return
72.65%
This Fund
S&P 500
This Quarter
Est. Return
+13.99%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$216M
AUM Growth
+$6.9M
(+3.3%)
Cap. Flow
-$12.7M
Cap. Flow
% of AUM
-5.89%
Top 10 Holdings %
Top 10 Hldgs %
39.36%
Holding
92
New
7
Increased
29
Reduced
20
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Evotec
EVO
|
+$1.42M |
| 2 |
Corvus Pharmaceuticals
CRVS
|
+$1.3M |
| 3 |
Amgen
AMGN
|
+$1.04M |
| 4 |
VanEck Gold Miners ETF
GDX
|
+$620K |
| 5 |
Structure Therapeutics
GPCR
|
+$544K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPDR Gold Trust
GLD
|
+$908K |
| 2 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$562K |
| 3 |
Xencor
XNCR
|
+$558K |
| 4 |
Oracle
ORCL
|
+$484K |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$462K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.72% |
| 2 | Technology | 27.13% |
| 3 | Consumer Discretionary | 7.96% |
| 4 | Communication Services | 7.9% |
| 5 | Financials | 4.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
CALL
O-I Glass
OI
$1.18B
| $236K | 0.11% |
16,000
| – | – |
|
77
Palo Alto Networks
PANW
$256B
| $215K | 0.1% |
+1,050
| New | +$195K |
|
|
78
State Street Energy Select Sector SPDR ETF
XLE
$39B
| $212K | 0.1% |
5,000
-13,500
| -73% | -$562K |
|
79
CALL
Teva Pharmaceuticals
TEVA
$40.2B
| $126K | 0.06% |
7,500
| – | – |
|
80
CALL
Burford Capital
BUR
$914M
| $49.9K | 0.02% |
+3,500
| New | +$45.7K |
|
81
Altimmune
ALT
$568M
| $41.7K | 0.02% |
10,770
-11,000
| -51% | -$59.5K |
|
82
Ardelyx
ARDX
$1.24B
| $39.2K | 0.02% |
+10,000
| New | +$41.3K |
|
|
83
CALL
Corvus Pharmaceuticals
CRVS
$1.09B
| $10K | ﹤0.01% |
2,500
-2,500
| -50% | -$9.1K |
|
84
Equillium
EQ
$142M
| – | – |
-39,492
| Closed | -$15.5K |
|
|
85
PUT
SPDR Gold Trust
GLD
$131B
| – | – |
-8,000
| Closed | -$2.31M |
|
86
PUT
Ionis Pharmaceuticals
IONS
$8.92B
| – | – |
-1,500
| Closed | -$45.3K |
|
87
CALL
LENSAR
LNSR
$64.8M
| – | – |
-2,000
| Closed | -$28.2K |
|
88
PUT
Vanguard S&P 500 ETF
VOO
$956B
| – | – |
-35,000
| Closed | -$18M |
|
89
Wolfspeed
WOLF
$1.04B
| – | – |
-27,500
| Closed | -$84.2K |
|
90
CALL
Zoom
ZM
$27.1B
| – | – |
-5,000
| Closed | -$369K |
|
|
ITCI
91
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-3,500
| Closed | -$462K |
|
Similar funds
JIC
CIM
AIM
MWM
RCP
AWM
HPM
CAG
DCF Advisers's Q2 2025 Portfolio in Review
As of Q2 2025, DCF Advisers held 92 positions worth $216M, up 3.3% from $209M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
DCF Advisers withdrew a net $12.7M in Q2 2025, closing 8 positions and reducing 20 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $462K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 31% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, DCF Advisers opened a new position in Structure Therapeutics worth $513K.
- DCF Advisers's largest Q2 2025 buy was Structure Therapeutics: 24,750 shares worth $513K.
- DCF Advisers added most to Evotec in Q2 2025, an estimated $1.42M increase.
- DCF Advisers's biggest Q2 2025 reduction was SPDR Gold Trust, cutting an estimated $908K.
- DCF Advisers fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $462K.
- DCF Advisers's ten largest holdings make up 39% of its $216M portfolio in Q2 2025.
- DCF Advisers opened 7 new positions and closed 8 in Q2 2025.
- DCF Advisers's portfolio value rose 3.3% quarter-over-quarter to $216M.
Based on DCF Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.